SHIFT AI Newsroom · GLOBAL
Trial Compares BI 456906 and Semaglutide in Obesity
A study is investigating the effects of BI 456906 and semaglutide on glucagon receptor activity in the liver in people with obesity.
A new trial has been registered to compare the effects of BI 456906 and semaglutide on glucagon receptor activity in the liver in people with obesity. The trial is currently in the recruitment phase.
What this means in the UK
This trial may provide insight into potential new treatments for obesity, which is a significant health concern in the UK.
Known facts
- A study is investigating the effects of BI 456906 and semaglutide on glucagon receptor activity in the liver in people with obesity.